Changchun Genescience Pharmaceutical Co., Ltd.

This study tests a new drug called GenSci142, given as a vaginal capsule, for treating bacterial vaginosis (BV). About 30 women with BV will receive either GenSci142 or a standard antibiotic cream to compare safety and how well each works. The goal is to see if the new capsule is…

This study tests a new drug, GenSci048, in people with active non-infectious uveitis, an inflammatory eye disease. The trial will compare two doses of GenSci048 against a placebo to see if it can control the disease and reduce treatment failure. About 111 adults with active uveit…

This study tests a new medicine called GenSci134, a long-acting growth hormone, in 128 children with growth hormone deficiency (GHD). The goal is to find the best dose and see if it is safe and helps children grow taller. In the first part, children get one shot of GenSci134; in …

This study tests a new drug called GenSci134, a growth hormone injection, in 128 children with idiopathic short stature (short height with no known cause). The trial has two parts: first, a single-dose phase to check safety and how the body processes the drug; second, a multiple-…

This early-stage trial tests a new drug called GenSci142 in 30 healthy Chinese women to see if it is safe and how the body processes it. Participants receive a single dose of the drug or a placebo, and are monitored for side effects for 15 days. The goal is to gather safety infor…

This study tests an oral medicine called GS3-007a for children with growth hormone deficiency. In the first part, kids receive different doses or a placebo for 14 days to check safety. In the second part, they take the chosen dose or a standard injection for 52 weeks to see how w…

This study looks at a fertility drug called corifollitropin alfa in women aged 36 to 40 who are doing IVF. The goal is to see if the drug is safe and helps produce eggs. Researchers will track side effects and pregnancy rates over one year.

This study looks at whether adding a special form of megestrol acetate to standard treatment can help improve appetite and body weight in people with advanced liver cancer who are experiencing cachexia (severe weight loss and muscle wasting). About 68 participants will be randoml…

This early-phase trial tests the safety and tolerability of a new drug called GenSci155 in 68 healthy adults aged 18-60. Participants receive either the drug or a placebo by IV injection, with doses increasing in later groups. The study does not aim to treat any disease, but to g…

This early-stage study looks at how the drug GS1-144 moves through the bodies of women with and without liver problems. About 24 women aged 18 to 70 will take part. The goal is to measure drug levels and see if liver function affects them. No treatment is being tested.